CIK 0001604821 · Large accelerated filer
Natera, Inc.
Sign in to watch- Ticker
- NTRA
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 010894487
- Phone
- 650-249-9090
- Business address
- 13011 MCCALLEN PASS, BUILDING A SUITE 100, AUSTIN, TX, 78753
- Former names
- Natera, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $104,832,418
- in 28 filings, $104.8M under 10b5-1 plans
Net −$104,832,418. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Rabinowitz Matthew −$72.3M EXECUTIVE CHAIRMAN sold 9% of stake
- Sheena Jonathan −$13.8M Director sold 83% of stake
- Moshkevich Solomon −$9.5M PRESIDENT, CLINICALDIAGNOSTICS sold 21% of stake
- Chapman Steven Leonard −$5.0M CEO AND PRESIDENT sold 12% of stake
- Brophy Michael Burkes −$2.5M CHIEF FINANCIAL OFFICER sold 11% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-04-03 | Sheena Jonathan Director | Sale 10b5-1 | −396 | $139.56 | $55K | 40,669 |
| 2025-04-03 | Sheena Jonathan Director | Sale 10b5-1 | −287 | $140.57 | $40K | 40,382 |
| 2025-04-03 | Sheena Jonathan Director | Sale 10b5-1 | −100 | $141.28 | $14K | 40,282 |
| 2025-04-03 | Sheena Jonathan Director | Sale 10b5-1 | −260 | $137.08 | $36K | 41,522 |
| 2025-04-03 | Sheena Jonathan Director | Sale 10b5-1 | −490 | $138.55 | $68K | 41,032 |
| 2025-04-03 | Sheena Jonathan Director | Sale 10b5-1 | −395 | $140.00 | $55K | 40,637 |
| 2025-04-03 | Sheena Jonathan Director | Sale 10b5-1 | −355 | $140.94 | $50K | 40,282 |
| 2025-04-01 | Marcus Gail Boxer Director | Option exercise 10b5-1 | +1,130 | $7.86 | $9K | 10,834 |
| 2025-04-01 | Marcus Gail Boxer Director | Option exercise 10b5-1 | +2,870 | $24.42 | $70K | 13,704 |
| 2025-04-01 | Marcus Gail Boxer Director | Sale 10b5-1 | −398 | $139.33 | $55K | 13,306 |
| 2025-04-01 | Marcus Gail Boxer Director | Sale 10b5-1 | −1,512 | $140.17 | $212K | 11,794 |
| 2025-04-01 | Marcus Gail Boxer Director | Sale 10b5-1 | −1,528 | $141.13 | $216K | 10,266 |
| 2025-04-01 | Marcus Gail Boxer Director | Sale 10b5-1 | −365 | $142.25 | $52K | 9,901 |
| 2025-04-01 | Marcus Gail Boxer Director | Sale 10b5-1 | −197 | $142.82 | $28K | 9,704 |
| 2025-04-01 | Marcus Gail Boxer Director | Option exercise · Stock Option (right to buy) 10b5-1 | −1,130 | 0 | ||
| 2025-04-01 | Marcus Gail Boxer Director | Option exercise · Stock Option (right to buy) 10b5-1 | −2,870 | 8,299 | ||
| 2025-04-01 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Sale 10b5-1 | −1,291 | $139.78 | $180K | 143,491 |
| 2025-04-01 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Sale 10b5-1 | −1,270 | $140.70 | $179K | 142,221 |
| 2025-04-01 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Sale 10b5-1 | −439 | $141.90 | $62K | 141,782 |
| 2025-04-01 | Chapman Steven Leonard CEO AND PRESIDENT | Sale 10b5-1 | −2,515 | $139.39 | $351K | 210,026 |
Page 50 of 55 · 1,093 trades